ALZHEIMER S DISEASE RELATED BIOMARKERS FOLLOWING SARS-COV-2 INFECTION

Brief description of study

A prospective, observational, longitudinal cohort study (n=300) of either: SARS-CoV-2 laboratory positive subjects who have new objective cognitive abnormalities within 12 months of SARS-CoV-2 infection (COVID+Cog+); SARS-CoV-2 laboratory positive subjects without new cognitive findings within 12 months of SARS-CoV-2 infection (COVID+Cog-); or 3) SARS-CoV-2 negative subjects who are cognitively normal (Controls). Participants will have demographic and medical history collected, along with cognitive, biomarker (plasma, MRI, digital), as well as olfactory testing approximately every 12 months over the course of 5 years.


Clinical Study Identifier: s22-00517
Principal Investigator: Thomas M Wisniewski.
Other Investigators: Arjun V. Masurkar, Sujata P. Thawani, Yulin Ge, Allal Boutajangout, Jennifer A. Frontera, Laura J Balcer.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.